A Phase Ii Trial Of Selumetinib (Azd6244) In Women With Recurrent Low-Grade Serous Carcinoma Of The Ovary Or Peritoneum: A Gynecologic Oncology Group Trial

BACKGROUND: Because low grade serous carcinoma of the ovary is relatively chemo resistant disease, this study evaluated Selumetinib (AZD6244), an inhibitor of mitogen-activated protein kinase kinase (MEK-1/2), and explored associations between RAS, and RAF family mutations with clinical outcome. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Farley, John, Brady, William E., Vathipadiekal, Vinod, Lankes, Heather A., Coleman, Robert, Morgan, Mark A., Mannel, Robert, Yamada, S. Diane, Mutch, David, Rodgers, William H., Birrer, Michael, Gershenson, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627419/
https://ncbi.nlm.nih.gov/pubmed/23261356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70572-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados